References
- Senovilla L, Aranda F, Galluzzi L, Kroemer G. Impact of myeloid cells on the efficacy of anticancer chemotherapy. Curr Opin Immunol 2014; 30:24-31; PMID:24950501; https://doi.org/10.1016/j.coi.2014.05.009
- Mantovani A, Locati M. Macrophage metabolism shapes angiogenesis in tumors. Cell Metab 2016; 24:653-4; PMID:27829135; https://doi.org/10.1016/j.cmet.2016.10.016
- Mantovani A, Marchesi F, Malesci A, Laghi L, Allavena P. Tumour-associated macrophages as treatment targets in oncology. Nat Rev Clin Oncol 2017; PMID:28117416; https://doi.org/10.1038/nrclinonc.2016.217
- Mok S, Koya RC, Tsui C, Xu J, Robert L, Wu L, Graeber TG, West BL, Bollag G, Ribas A. Inhibition of CSF-1 receptor improves the antitumor efficacy of adoptive cell transfer immunotherapy. Cancer Res 2014; 74:153-61; PMID:24247719; https://doi.org/10.1158/0008-5472.CAN-13-1816
- Shiao SL, Ruffell B, DeNardo DG, Faddegon BA, Park CC, Coussens LM. TH2-polarized CD4(+) T cells and macrophages limit efficacy of radiotherapy. Cancer Immunol Res 2015; 3:518-25; PMID:25716473; https://doi.org/10.1158/2326-6066.CIR-14-0232
- Pyonteck SM, Akkari L, Schuhmacher AJ, Bowman RL, Sevenich L, Quail DF, Olson OC, Quick ML, Huse JT, Teijeiro V et al. CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat Med 2013; 19:1264-72; PMID:24056773; https://doi.org/10.1038/nm.3337
- Vacchelli E, Bloy N, Aranda F, Buque A, Cremer I, Demaria S, Eggermont A, Formenti SC, Fridman WH, Fucikova J et al. Trial watch: immunotherapy plus radiation therapy for oncological indications. Oncoimmunology 2016; 5:e1214790; PMID:27757313; https://doi.org/10.1080/2162402X.2016.1214790
- Buque A, Bloy N, Aranda F, Cremer I, Eggermont A, Fridman WH, Fucikova J, Galon J, Spisek R, Tartour E et al. Trial watch-small molecules targeting the immunological tumor microenvironment for cancer therapy. Oncoimmunology 2016; 5:e1149674; PMID:27471617; https://doi.org/10.1080/2162402X.2016.1149674
- Guerriero JL, Sotayo A, Ponichtera HE, Castrillon JA, Pourzia AL, Schad S, Johnson SF, Carrasco RD, Lazo S, Bronson RT et al. Class IIa HDAC inhibition reduces breast tumours and metastases through anti-tumour macrophages. Nature 2017; 543:428-32; PMID:28273064; https://doi.org/10.1038/nature21409
- Lin EY, Nguyen AV, Russell RG, Pollard JW. Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J Exp Med 2001; 193:727-40; PMID:11257139; https://doi.org/10.1084/jem.193.6.727
- Kroemer G, Senovilla L, Galluzzi L, Andre F, Zitvogel L. Natural and therapy-induced immunosurveillance in breast cancer. Nat Med 2015; 21:1128-38; PMID:26444637; https://doi.org/10.1038/nm.3944